Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells

Yumin Oh, Ogyi Park, Magdalena Swierczewska, James P. Hamilton, Jong Sung Park, Tae Hyung Kim, Sung Mook Lim, Hana Eom, Dong Gyu Jo, Choong Eun Lee, Raouf Kechrid, Panagiotis Mastorakos, Clark Zhang, Sei Kwang Hahn, Ok Cheol Jeon, Youngro Byun, Kwangmeyung Kim, Justin Hanes, Kang Choon Lee, Martin G. PomperBin Gao, Seulki Lee

Research output: Contribution to journalArticlepeer-review

56 Scopus citations


Liver fibrosis is a common outcome of chronic liver disease that leads to liver cirrhosis and hepatocellular carcinoma. No US Food and Drug Administration–approved targeted antifibrotic therapy exists. Activated hepatic stellate cells (aHSCs) are the major cell types responsible for liver fibrosis; therefore, eradication of aHSCs, while preserving quiescent HSCs and other normal cells, is a logical strategy to stop and/or reverse liver fibrogenesis/fibrosis. However, there are no effective approaches to specifically deplete aHSCs during fibrosis without systemic toxicity. aHSCs are associated with elevated expression of death receptors and become sensitive to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL)-induced cell death. Treatment with recombinant TRAIL could be a potential strategy to ameliorate liver fibrosis; however, the therapeutic application of recombinant TRAIL is halted due to its very short half-life. To overcome this problem, we previously generated PEGylated TRAIL (TRAILPEG) that has a much longer half-life in rodents than native-type TRAIL. In this study, we demonstrate that intravenous TRAILPEG has a markedly extended half-life over native-type TRAIL in nonhuman primates and has no toxicity in primary human hepatocytes. Intravenous injection of TRAILPEG directly induces apoptosis of aHSCs in vivo and ameliorates carbon tetrachloride-induced fibrosis/cirrhosis in rats by simultaneously down-regulating multiple key fibrotic markers that are associated with aHSCs. Conclusion: TRAIL-based therapies could serve as new therapeutics for liver fibrosis/cirrhosis and possibly other fibrotic diseases. (Hepatology 2016;64:209–223).

Original languageEnglish
Pages (from-to)209-223
Number of pages15
Issue number1
StatePublished - 1 Jul 2016

Bibliographical note

Publisher Copyright:
© 2015 by the American Association for the Study of Liver Diseases


Dive into the research topics of 'Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating activated hepatic stellate cells'. Together they form a unique fingerprint.

Cite this